Literature DB >> 15304090

Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions.

Robin M Hobbs1, Violeta Silva-Vargas, Richard Groves, Fiona M Watt.   

Abstract

Epidermal activation of Erk MAPK is observed in human psoriatic lesions and in a mouse model of psoriasis in which beta1 integrins are expressed in the suprabasal epidermal layers. Constitutive activation of the upstream kinase MEK1 causes hyperproliferation and perturbed differentiation of human keratinocytes in culture. It is not known, however, whether Erk activation in differentiating keratinocytes is sufficient to trigger hyperproliferation of basal keratinocytes and a skin inflammatory infiltrate. To investigate this, we expressed constitutively active MEK1 in the suprabasal epidermal layers of transgenic mice. Proliferation in the epidermal basal layer was stimulated and epidermal terminal differentiation was perturbed. Some older mice also developed papillomas. There was a large increase in T lymphocytes, dendritic cells, and neutrophils in the skin. The effects of suprabasal MEK1 on basal keratinocytes and leukocytes, cells that were transgene negative, suggested that MEK1 activity might stimulate cytokine release. Transgenic keratinocytes expressed elevated IL-1alpha and crossing the mice with mice overexpressing the IL-1 receptor in the epidermal basal layer led to exacerbated hyperproliferation and inflammation. These data suggest that activation of MEK1 downstream of beta1 integrins plays an important role in epidermal hyperproliferation and skin inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304090     DOI: 10.1111/j.0022-202X.2004.23225.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  33 in total

Review 1.  Psoriasis: what we have learned from mouse models.

Authors:  Erwin F Wagner; Helia B Schonthaler; Juan Guinea-Viniegra; Erwin Tschachler
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

2.  Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway.

Authors:  Christopher W Dawson; Louise Laverick; Mhairi A Morris; Giorgos Tramoutanis; Lawrence S Young
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

3.  Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate.

Authors:  Esther N Arwert; Rohit Lal; Sven Quist; Ian Rosewell; Nico van Rooijen; Fiona M Watt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 4.  Epithelial stem cells, wound healing and cancer.

Authors:  Esther N Arwert; Esther Hoste; Fiona M Watt
Journal:  Nat Rev Cancer       Date:  2012-02-24       Impact factor: 60.716

Review 5.  Cell-extracellular matrix interactions in normal and diseased skin.

Authors:  Fiona M Watt; Hironobu Fujiwara
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-04-01       Impact factor: 10.005

6.  Keratin 16 regulates innate immunity in response to epidermal barrier breach.

Authors:  Juliane C Lessard; Sylvia Piña-Paz; Jeremy D Rotty; Robyn P Hickerson; Roger L Kaspar; Allan Balmain; Pierre A Coulombe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

7.  Metalloproteinase-mediated, context-dependent function of amphiregulin and HB-EGF in human keratinocytes and skin.

Authors:  Stefan W Stoll; Jessica L Johnson; Ajay Bhasin; Andrew Johnston; Johann E Gudjonsson; Laure Rittié; James T Elder
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

8.  Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.

Authors:  Marianna Sadagurski; Shoshana Yakar; Galina Weingarten; Martin Holzenberger; Christopher J Rhodes; Dirk Breitkreutz; Derek Leroith; Efrat Wertheimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 9.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

Review 10.  Tracing the cellular origin of cancer.

Authors:  Cédric Blanpain
Journal:  Nat Cell Biol       Date:  2013-01-20       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.